Loading clinical trials...

In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis | Clinical Trials | Clareo Health

UNKNOWN

In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis

In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis

NCT02852850•Shandong University

Summary

Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with active ulcerative colitis will receive infliximab antibody therapy.

Exclusion Criteria

•Patients with impaired blood clotting.
•Patients with short bowel syndrome.
•Patients during the pregnancy and lactation period.
•Patients received enema therapy within 1 month before inclusion in the study, or had anti-TNF therapy within the last 12 months.
•Patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit.
•Patients with moderate to severe heart failure, active tuberculosis or acute infections.

Locations (1)

Department of Gastroenterology, Qilu Hospital, Shandong University

Jinan, Shandong, China

Key Dates

Start Date

January 1, 2016

Primary Completion Date

June 1, 2018

Last Updated

October 17, 2016

Enrollment

ESTIMATED participants

Conditions

Ulcerative Colitis

Contacts

Yanqing Li, PhD. MD.

CONTACT

86-531-82169236 liyanqing@sdu.edu.cn

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069

Ulcerative Colitis (UC)

View study

RECRUITINGPHASE2

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

NCT06975722

Ulcerative Colitis

View study

RECRUITINGPHASE3

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 17, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis

Inclusion Criteria

Exclusion Criteria

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects